People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...
While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.
In two new papers, researchers from The Jackson Laboratory (JAX) report the successful use of two approaches—gene therapy and ...
This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...
In two new papers, researchers from The Jackson Laboratory (JAX) report the successful use of two approaches -- gene therapy ...
NHS officials estimate around 50 people a year will receive treatment now it has been approved for use for certain patients with severe sickle cell disease. | ITV National News ...